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Trichloroethylene (TCE) and its metabolites
trichloroacetic acid (TCA) and dichloroacetic
acid (DCA) induce peroxisome proliferation
(PP) in rodents; only TCA and DCA activate
mouse and human PP-activated receptor α
(PPARα) in vitro, and TCA induces the most
sustained PP response (Bull 2000; Maloney
and Waxman 1999; Zhou and Waxman
1998). However, all three are relatively weak
inducers of PP compared with the pharmaceu-
tical drug Wyeth-14,463 (WY), which is con-
sidered to be the “model” agonist of PPARα
and thought to be responsible for PP. Modes
of action (MOAs) for TCE involving PP or
PPARα agonism generally have focused on
induction of liver tumors, for which associa-
tions with TCE and/or its metabolites have
been reported in both rodent bioassays 
and human epidemiologic studies [U.S.
Environmental Protection Agency (U.S. EPA)
2001; Wartenberg et al. 2000]. PPAR-inde-
pendent MOAs of TCE metabolites (e.g.,
inhibition of glutathione S-transferase ζ by
DCA or hypomethylation by TCA or DCA)
are discussed separately in Caldwell and
Keshava (2006).
There are a number of both long-standing
and emerging issues with respect to evaluating
the role of PPARα in MOAs for TCE toxicity.
The U.S. EPA draft TCE risk assessment (U.S.
EPA 2001) concluded that although PPARα
may play a role in liver tumor induction, the
role of its activation in the sequence of events
leading to tumorigenesis was not well deﬁned,
particularly due to uncertainties in the contri-
bution and cross-species relevance of extra-
peroxisomal effects from PPARα activation.
Moreover, a vast literature on PPARα agonists
has emerged investigating its potential role not
only in liver tumorigenesis but also in numer-
ous other diseases, toxic responses, and recep-
tor pathways. This suggests that investigation
of possible roles of PPARα agonism in the
MOAs of TCE toxicity should move beyond
examining only liver tumorigenesis.
In the present article we highlight some of
the recently published literature on PPARα for
TCE, its metabolites, and other PPARα ago-
nists to help inform and illustrate the key sci-
entiﬁc issues relevant to TCE risk assessment.
Although some scientific conclusions can be
drawn from this updated body of data, specu-
lation as to its impact on the final TCE risk
assessment would be premature at this point,
given the ongoing National Academy of
Sciences consultation discussed in the overview
article (Chiu et al. 2006) and the subsequently
planned revision of the U.S. EPA TCE risk
assessment. Therefore, the purpose here and
throughout this mini-monograph is to provide
a review of recently published scientiﬁc litera-
ture in the context of how it informs the key
scientiﬁc issues we believe to be most critical to
developing a revised risk assessment.
Recent Data on PPARα
Agonism and TCE
Recent efforts to elucidate the role of PPARα
agonism in TCE-induced toxicity have
focused on comparison of gene expression
changes with other agonists and/or the use of
PPARα knockout mice. Recent data on
DNA methylation changes and other MOAs
for a number of agonists, including TCE and
its metabolites DCA and TCA, are reported
elsewhere in this mini-monograph (Caldwell
and Keshava 2006). TCE-speciﬁc data using
DNA arrays and knockout mice remain lim-
ited and difﬁcult to interpret.
It is difﬁcult to discern a clear pattern of
common gene expression changes among
TCE and its metabolites or for peroxisome
proliferators in general for use in making
inferences regarding common MOAs. For
example, in a screening analysis of 148 genes
for xenobiotic-metabolizing enzymes, DNA
repair enzymes, heat-shock proteins (hsp),
cytokines, and housekeeping genes in mouse
liver, Bartosiewicz et al. (2001b) reported
TCE-induced up-regulation of only three
genes [hsp25 and hsp86, and cytochrome
P450 2a (cyp2a)] at the highest dose tested
(1,000 mg/kg) and repression of cyp2a at a
much lower single dose (10 mg/kg) of TCE
after a single intraperitoneal injection in corn
oil. Using a similar paradigm with 260 genes,
Bartosiewicz et al. (2001a) reported that expo-
sure to 500 mg/kg cloﬁbrate and 1,100 mg/kg
di(2-ethylhexyl)phthalate (DEHP) induced a
different pattern of transcription than did
TCE. DEHP and cloﬁbrate cause increases in
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Peroxisome proliferator–activated receptor α (PPARα) is thought to be involved in several different
diseases, toxic responses, and receptor pathways. The U.S. Environmental Protection Agency
2001 draft trichloroethylene (TCE) risk assessment concluded that although PPAR may play a
role in liver tumor induction, the role of its activation and the sequence of subsequent events
important to tumorigenesis are not well deﬁned, particularly because of uncertainties concerning
the extraperoxisomal effects. In this article, which is part of a mini-monograph on key issues in
the health risk assessment of TCE, we summarize some of the scientiﬁc literature published since
that time on the effects and actions of PPARα that help inform and illustrate the key scientific
questions relevant to TCE risk assessment. Recent analyses of the role of PPARα in gene expres-
sion changes caused by TCE and its metabolites provide only limited data for comparison with
other PPARα agonists, particularly given the difﬁculties in interpreting results involving PPARα
knockout mice. Moreover, the increase in data over the last 5 years from the broader literature on
PPARα agonists presents a more complex array of extraperoxisomal effects and actions, suggesting
the possibility that PPARα may be involved in modes of action (MOAs) not only for liver tumors
but also for other effects of TCE and its metabolites. In summary, recent studies support the con-
clusion that determinations of the human relevance and susceptibility to PPARα-related MOA(s)
of TCE-induced effects cannot rely on inferences regarding peroxisome proliferation per se and
require a better understanding of the interplay of extraperoxisomal events after PPARα agonism.
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thioesterase, cyp4a10, and insulin-like growth
factor (IGF), with clofibrate also inducing
greater expression of these genes and addi-
tional induction of cyp2b9, a fatty acid–bind-
ing protein, and metallothionein II. The
pattern of induction differed between kidney
and liver for DEHP and clofibrate. Collier
et al. (2003) reported 26 differentially
expressed mRNA transcripts in embryonic
hearts of Sprague-Dawley rats whose dams
were exposed to 1,100 ppm TCE through
drinking water between days 0 and 11 of preg-
nancy. Genes down-regulated with TCE
exposure appear to be those associated with
cellular housekeeping, cell adhesion, and
developmental processes, whereas TCE expo-
sure up-regulated expression of numerous
stress-response and homeostatic genes.
Two studies have used PPARα knockout
mice to investigate the importance of PPARα
to TCE toxicity. However, interpretation of
PPARα knockout mice data in general poses
some unique difﬁculties due to differences in
baseline responses, some of which were
observed in the TCE-speciﬁc studies as well.
In one study, Laughter et al. (2004) used
macroarrays containing approximately
1,200 genes and reported altered expression of
43 genes in the TCE-treated wild-type mice
and 67 genes in PPARα knockout mice after
3 days of exposure to up to 1,500 mg/kg/day
TCE. The authors reported that of the
43 genes with altered expression in wild-type
mice after TCE exposure, 40 genes were
dependent on PPARα. These genes included
cyp4a12, epidermal growth factor receptor,
and additional genes involved in cell growth.
However, the interpretation of this informa-
tion is difﬁcult because a comparison of gene
expression proﬁles between controls (wild-type
and PPARα knockout) was not reported.
Moreover, after 3 weeks of TCE treatment
(0–1,500 mg/kg via gavage), Laughter et al.
(2004) reported toxicity at the 1,500 mg/kg
level in the knockout mice that was not
observed in the wild-type mice; all knockout
mice were moribund and had to be removed
from the study. Inspections of livers and kid-
neys from the group did not reveal overt signs
of toxicity that would lead to morbidity. At
the same dose, wild-type mice exhibited mild
granuloma formation with calcification or
mild hepatocyte degeneration with centrilobu-
lar hepatocyte hypertrophy. A TCE treat-
ment–related increase in liver weight was
reported in wild-type mice but not in knock-
out mice. However, knockout mice had a
greater liver-to-body weight ratio than did
wild-type mice at all levels of exposure, includ-
ing controls, making detection of a TCE-
induced change difficult. Similarly, the
knockout mice also had higher baseline levels
of hepatocyte proliferation. Both knockout
and wild-type mice appeared to have similar
levels of hepatocyte proliferation after
1,000 mg/kg TCE, with a high variability in
response. No analysis was reported to deter-
mine a statistical difference in proliferation
between the two types of mice as a conse-
quence of TCE exposure. Kidney-to-body
weight ratios were increased in wild-type but
not in knockout mice compared with controls.
No changes in kidney weights were reported
after 3 weeks of exposure.
In an earlier study, Nakajima et al. (2000)
reported that the number of peroxisomes in
hepatocytes increased by 2-fold in wild-type
mice but not in PPARα knockout mice 
after 2 weeks of TCE exposure by gavage
(0.75 g/kg). However, TCE induced increased
liver weight in both male and female wild-type
and knockout mice, suggesting hepatic 
effects independent of PPARα activation.
Interestingly, Laughter et al. (2004) reported no
difference in liver-to-body weight ratios
between wild-type and knockout mice after
1 week of exposure to 2.0 g/L TCA and only a
small difference after 1 week of 2.0 g/L DCA.
The authors suggested liver weight changes as a
surrogate for peroxisomal proliferative activity,
although neither PP nor changes in glycogen
content (which also can affect weight) of the
liver were directly measured.
MOAs for Liver Toxicity
Klaunig et al. (2003) proposed an MOA for
liver carcinogenicity in rodents of PPARα acti-
vation, associated PP, increased cell prolifera-
tion, decreased apoptosis, and clonal expansion
of preneoplastic cells, but there are notable
inconsistencies with this hypothesis. Long-term
carcinogenicity studies of the PPARα agonist
gemfibrozil (GEM) showed a dose-related
increase in liver tumors in male rats, whereas in
females a dose-dependent decrease in liver
tumors was reported (International Agency for
Research on Cancer 1996). Klaunig et al.
(2003) place substantial weight on PP as an
associative event in their proposed MOA, view-
ing PP as an indicator of sensitivity to hepato-
carcinogenic effects. However, studies in rats
with two PPARα agonists, WY and DEHP,
demonstrated that doses that produced equiva-
lent levels of hepatic PP, measured as peroxi-
some number and peroxisomal enzyme activity,
produced markedly different liver tumor inci-
dences. The degree of PP correlated poorly with
the relative hepatocarcinogenicity of DEHP
and WY but was correlated with the ability to
induce a persistent increase in replicative DNA
synthesis (Marsman et al. 1988).
In another study Reddy and Rao (1989)
hypothesized MOA is DNA damage caused by
marked increases in free radical–generating
enzymes of the peroxisomal β-oxidation
through hydrogen peroxide. However,
Bannasch (1996) noted that this hypothesis is
not supported by the ﬁndings in rats treated
with the peroxisome proliferator dehydro-
epiandrosterone, a potential natural regulator
of the peroxisomal compartment. Amphophilic
cell foci preceding the appearance of hepatocel-
lular neoplasms do not develop from the
perivenular zones, in which the most pro-
nounced PP occurs but from the periportal
areas in which the prevailing cellular alteration
is proliferation of mitochondria (Bannasch
1996). Interestingly, Nakajima et al. (2000)
also reported that TCE induced peroxisomes
in perivenular but not in periportal areas of
mice liver.
One study showed that extraperoxisomal
effects of PPARα agonists that may be related
to tumor induction are effects on mitochon-
dria, which have a role in several aspects of
tumor biology and whose DNA may have
increased susceptibility. Zhou and Wallace
(1999) reported that GEM and WY induced
the mitochondrial permeability transition as
characterized by calcium-induced swelling and
depolarization of membrane potential, both of
which were inhibited by cyclosporine A.
Fenofibrate, clofibrate, ciprofibrate, and
DEHP, on the other hand, caused a direct
dose-dependent depolarization of mitochondr-
ial membrane potential. However, the mecha-
nism of membrane depolarization varied
among the test chemicals. Bezafibrate and
TCE elicited no effect on succinate-supported
mitochondrial bioenergetics. The authors con-
cluded that most but not all the peroxisome
proliferators they studied interfered with mito-
chondrial bioenergetics and that the specific
biomolecular mechanism differed among the
individual compounds. Peroxisome prolifera-
tors have also been reported to induce pro-
nounced mitochondrial proliferation and
increased activity of mitochondrial enzymes in
liver tumors (Bannasch et al. 2001).
Polyak et al. (1998) have examined mito-
chondria and neoplasia, primarily because of
their role in apoptosis and other aspects of
tumor biology. The mitochondrial genome is
particularly susceptible to mutations because of
the high level of reactive oxygen species genera-
tion in this organelle coupled with a low level of
DNA repair. The authors reported mutations
in the mitochondrial genome in most human
colorectal cancers examined. Petros et al. (2005)
reported mutations in the mitochondrial DNA
(mtDNA) that have been found to fulﬁll all the
criteria expected for pathogenic mutations caus-
ing prostate cancer. Booker et al. (2006)
reported that the highly polymorphic mito-
chondrial genome, which is separate from
nuclear DNA, confers an inherited cancer risk
for prostate and renal cancers. Possible effects of
peroxisome proliferators on mitochondrial
genomics have not been investigated.
Another area of active investigation has
been whether PPARα agonists activate
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cells independently of PPARα activation and
whether such activation may be necessary for
tumor induction, particularly due to their role
in parenchymal cell proliferation and apopto-
sis suppression (Hasmall et al. 2001; Holden
et al. 2000; Parzefall et al. 2001; Peters et al.
2000; Roberts et al. 2002; Rusyn et al. 2000,
2001). Although the hypothesized MOA for
induction of acyl–CoA oxidase (ACO) lead-
ing to increased production of H2O2 and
DNA damage seems unlikely, free radicals
may be important in signaling Kupffer cells to
produce mitogenic cytokines [e.g., tumor
necrosis factor α (TNF-α)].
Rusyn et al. (2000, 2001) suggest that cell
proliferation and tumors require parenchymal
cell PPARα and TNF-α production by Kupffer
cells. They also suggest that peroxisome prolif-
erators increase free radicals in the liver before
peroxisomal oxidases are induced and activate
the transcription factor nuclear factor κB
(NF-κB; one of the major regulators of TNF-α
expression) in Kupffer cells. Interestingly, they
report that corn oil (often used as a vehicle)
rapidly activated NF-κB in Kupffer cells and
triggered production of low levels of TNF-α.
Other studies support TNF-α acting down-
stream or independently of PPARα to mediate
the suppression of apoptosis and induction of
DNA synthesis by peroxisome proliferators
(Holden et al. 2000; Peters et al. 2000; Roberts
et al. 2002). Klaunig et al. (2003) noted that
responsiveness (or lack thereof) in human hepa-
tocyte assay systems could be linked to removal
of Kupffer cells during preparation.
Pleiotropic Responses and
Actions of PPARα
Although studies of TCA, DCA, and other
PPARα agonists in human hepatocyte cultures
seem to indicate that the human liver is refrac-
tory to markers of PP (e.g., Walgren et al.
2000a, 2000b), humans are responsive to at
least some other effects from PPARα agonism,
as evidenced by the efﬁcacy of hypolipidemic
ﬁbrate drugs. An extensive research effort into
PPARs, much of it published since 2001, has
been set off by evidence that highly prevalent
chronic diseases such as diabetes, obesity, ath-
erosclerosis, and cancer may involve PPAR
activity and may be affected by PPAR agonists
such as thiazolidinediones and fibrates
(Kersten et al. 2000). Table 1 summarizes
some of the recent literature regarding activi-
ties and effect of activation of the PPARα
receptor, demonstrating its pleiotropic nature.
Along with the liver, other target organs and
systems affected include muscle, cardiovascu-
lar system, small intestine, testes, ovary, thy-
roid, adrenal axis, and immune system.
In the liver, PPARα responses involve not
only the parenchymal cells of the liver (hepato-
cytes), but also macrophages (Kupffer cells).
Activities affected include lipid and glucose
metabolism; bile acid synthesis; macrophage
cholesterol homeostasis, inflammatory cyto-
kine production, and recruitment to inflam-
matory sites; actions and control of hormones
(glucocorticoids, growth hormones thyroid
estrogen); and protein expression (those
involved with all stages of atherosclerosis, liver
fatty acid binding, male rat-speciﬁc α2µ-globu-
lin, a mouse homologue of α2µ, glutathione
S-transferase, glutathione reductase, and the
CYP genes cyp2b, cyp2c, cyp3a, cyp1a1, and
cyp4a). Effects on the vulnerability of the liver
to other insults such as acetaminophen toxicity
have also been reported. Moreover, because
some of these extraperoxisomal effects of
PPARα agonists may not depend on interac-
tion with PPARα, Scatena et al. (2003) suggest
that the biochemical proﬁle and a therapeutic
role of this class of PPAR ligands are more
complex than previously proposed.
That PPARα agonism results in pleiotropic
responses should not be surprising. Poole et al.
(2001) have shown that after an agonist binds
to the PPARα receptor, it heterodimerizes with
the retinoid X receptor, with the heterodimer
interacting with DNA sequences or response
elements found in a large number of responsive
genes. An examination of the full spectrum of
PPARα activity is necessary to make a compre-
hensive comparison with TCE-induced effects,
and a number of issues in examining and inter-
preting these data are discussed in the sections
that follow.
Gene regulation and expression. There is a
growing database on the differences in
responses among PPARα agonists as well as
the pleiotropic responses they induce. Some
agonists have been shown to display activity
toward more than one receptor (Berger and
Moller 2002; Liu et al. 2005), which compli-
cates interpretation of data across chemicals.
Using the same paradigm, an examination of
several recent publications, summarized in
Table 2, reveals inconsistent results between
PPARα agonists, paradoxes between mRNA
and protein expression, strain, gender, and
species differences in response to the same
chemical, and time-dependent differences in
response (Fan et al. 2003, 2004; O’Brien et al.
2001; Poole et al. 2001).
In addition male rats have been reported to
be more responsive to ﬁbrates than are female
rats. Jalouli et al. (2003) reported that male rats
had higher levels of hepatic PPARα mRNA
and protein than did female rats. The authors
suggested that sex hormones regulate the sex
difference in hepatic PPARα levels but not via
the sexually dimorphic growth hormone secre-
tory pattern. Nakajima et al. (2000) reported
no remarkable sex difference in TCE-induced
PP in wild-type mice, as measured morpho-
logically, but a markedly higher induction of
several enzymes and PPARα protein and
mRNA was found in the liver of males after
2 weeks of exposure.
As mentioned above, PPARα knockout
mice have been used to make inferences about
PPARα expression effects, but no common
pattern of gene expression has emerged. Valles
et al. (2003) reported exposure of diisononyl
phthalate in B6C3F1 and SV129 wild-type
and knockout mice to show a varied pattern of
gene expression dependent on gender and age.
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Table 1. Recent literature on effects associated with PPARα agonism or related to its mechanisms of action.
Effect Reference
Role in chronic diseases: obesity, atherosclerosis, Barbier et al. (2002), Berger and Moller (2002), Berger and 
diabetes, inﬂammation, and cancer Wagner (2002), Guerre-Millo et al. (2001), Hays et al. (2005), 
Jove et al. (2004), Kersten et al. (2000), Lacquemant et al. 
(2000), Liu et al. (2005), Moennikes et al. (2003), Moller and 
Berger (2003), Robitaille et al. (2004), Shankar et al. (2003), 
Vohl et al. (2000), Vosper et al. (2002)
Role in fasting Escher et al. (2001), Kersten et al. (2001), Poirier et al. (2001)
Changes in susceptibility to disease:  Brisson et al. (2002), Chao et al. (2002), Chen et al. (2000, 2002), 
cardiomyopathies and cardiac cell metabolism, Eurlings et al. (2002), Harris et al. (2004), Huss and Kelly (2005),
familial combined hyperlipidemia, increased  Huss et al. (2005), Jamshidi et al. (2002), Jiang et al. (2004), 
susceptibility from aging, and acetaminophen  Nohammer et al. (2003), Watanabe et al. (2000), Youssef and 
hepatotoxicity Badr (2002), Youssef et al. (2003)
Extrahepatic effects: muscle lipid homeostasis,  Michalik et al. (2001), Muoio et al. (2002), Poirier et al. (2001)
liver fatty acid–binding protein (liver and small 
intestine), and early inﬂammation phase of 
the healing
Cell signaling effects: TNF-α, growth hormone  Barbier et al. (2003a, 2003b), Holden et al. (2000), Pan et al.
and STAT5b, L-pyruvate kinase (glycolytic  (2000), Peters et al. (2000), Roberts et al. (2002), Rusyn et al. 
enzyme), and bile acid synthesis and catabolism (2000), Sinal et al. (2001), Zhou and Waxman (1999), 
in the liver (UDP-glucuronosyltransferase) Zhou et al. (2002)
Phase I and II enzymes—CYP expression changes: Fan et al. (2003, 2004), Kim et al. (2003), O’Brien et al. (2001), 
CYP genes (including CYP2B, CYP2C, CYP3A,  Ripp et al. (2003), Seree et al. (2004)
CYP1A1, and CYP4A family members),
modulation of glutathione defense
Endocrine effects: ovarian function, estrogen  Dufour et al. (2003), Gazouli et al. (2002), Kim et al. (2003), Klotz
action, steroid metabolism enzymes, testicular  et al. (2000), Komar et al. (2001), Miller et al. (2001), Parks 
degeneration, and thyroid hormone action et al. (2000), Poole et al. (2001), Xu et al. (2001), Zhu et al. (1999)They suggested that some changes in gene
expression were dependent on PPARα activity
and others were not. Macdonald et al. (2001)
reported alteration of 59 PPARα- and peroxi-
some-dependent proteins after DEHP treat-
ment. Proteins identiﬁed as being regulated by
PPARα were known to be involved not only in
lipid metabolism pathways but also in amino
acid and carbohydrate metabolism, mitochon-
drial bioenergetics, and stress responses, includ-
ing several genes not previously reported to be
regulated by PPARα. Hasmall et al. (2002)
reported a 3- to 7-fold down-regulation of
lactoferrin mRNA in response to DEHP in
wild-type versus PPARα knockout mice. The
authors suggested that the regulation of iron-
binding proteins by PPARα ligands plays a
role in peroxisome proliferator–mediated liver
growth but not in PP.
Another approach for investigation of
PPARα related effects is to study its overex-
pression. Jia et al. (2003) reported that disrup-
tion of the inducible β-oxidation pathway 
in mice at the level of fatty ACO results in
spontaneous PP and sustained activation of
PPARα. Meyer et al. (2003) used cDNA
microarrays to study the expression proﬁles of
26 hepatocellular carcinomas developing spon-
taneously in peroxisomal fatty ACO knockout
mice. Comparisons of the knockout mouse
liver tumor expression profiles with those
induced by ciproﬁbrate or diethylnitrosamine
showed that these mice shared a number of
deregulated (up- or down-regulated) genes
with ciproﬁbrate-induced liver tumors.
Use of PPARα knockout mice to study
MOA. Several studies have used PPARα
knockout mice to try to determine specific
responses associated with PPAR agonism and
Peroxisome proliferation and TCE toxicity
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Table 2. Examples of chemical-, gender-, species-, and PPARα polymorphism-dependent responses to PPARα agonists.a
Parameter Test subjects WY DBP GEM DEHP
NADPH–CYP oxidoreductase
mRNA F-344 male rat ↑ 4.4-fold ↑ 2.2-fold No change —
F-344 female rat  ↑ 7.2-fold ↑ 5.1-fold ↑ 4.4-fold —
Wild-type male mouse ↑ 4.6-fold — — ↑ 5.8-fold
PPARα null male mouse No change — — No change
Protein F-344 male rat ↓ to 29% No change ↓ to 18% —
F-344 female rat No change ↑ 3.2-fold No change —
SD male rat ↓ to 40% — ↓ to 14% —
Wild-type male mouse ↓ to 4% — — ↓ to 12%
PPARα null male mouse No change — — ↑ 2.0-fold
Nonspeciﬁc carboxyesterase proteinb
ES-4 F-344 male rat ↓ to 30% No change ↓ to 15% —
F-344 female rat No change No change ↑ 1.6-fold —
SD male rat (#1) ↓ to 12% ↓ to 39% ↓ to 32% —
SD male rat (#2) ↓ to 13% ↓ to 63% ↓ to 16% —
Wild-type male mouse No change — — No change
PPARα male null mouse No change — — No change
ES-10 F-344 male rat ↓ to 1% No change ↓ to 10% —
F-344 female rat ↓ to 10% ↑ 2.0-fold No change —
SD male rat (#1) ↓ to 7% ↓ to 59% ↓ to 16% —
SD male rat (#2) ↓ to 8% ↓ to 60% ↑ 1.4-fold —
Wild-type male mouse No change — — No change
PPARα null male mouse No change — — ↓ to 50%
2α-Testosterone hydroxylase activity F-344 male rat ↓ to < 1% ↓ to 43% ↓ to 31% —
6β-Testosterone hydroxylase activity F-344 male rat No change ↑ 2.6-fold ↑ 2.0-fold —
7α-Testosterone hydroxylase activity F-344 male rat No change No change No change —
16α-Testosterone hydroxylase activity F-344 male rat ↓ to 4% ↓ to 47% ↓ to 35% —
16β-Testosterone hydroxylase activity F-344 male rat ↑ 2.3-fold ↑ 3.2-fold ↑ 3.6-fold —
Androstenedione hydroxylase activity F-344 male rat ↓ to 24% No change No change —
CYP3A11 mRNA (6α-testoserone hydroxylase) Wild-type male mouse ↓ to 40% — — ↑ 5.7-fold
PPARα null male mouse ↑ 1.9-fold — — ↑ 5.7-fold
CYP3A2 mRNA F-344 male rat ↓ to 25% No change ↓ to 36% —
CYP3A2 proteinb F-344 male rat ↓ to 13% ↑ 1.9-fold No change —
F-344 female rat No change ↑ 5.0-fold ↑ 5.0-fold —
SD male rat (#1) ↓ to 15% ↓ to 57% No change —
SD male rat (#2) ↓ to 3% No change No change —
CYP3A1 protein F-344 male rat ↑ 11-fold ↑ 15-fold ↑ 2-fold —
F-344 female rat ↓ to 42% ↑ 4.6-fold ↓ to 50% —
CYP2B1 protein F-344 male rat No change ↑ 2.4-fold No change —
F-344 female rat No change ↑ 8.0-fold ↑ 3.9-fold —
CYP4A protein F-344 male rat ↑ > 80-fold ↑ > 60-fold ↑ > 16-fold —
F-344 female rat ↑ 60-fold No change No change —
Estrogen sulfotransferase protein F-344 male rat ↓ to 2% ↓ to 8% ↓ to12% —
F-344 female ratc ↓↓↓ —
Glutathione S-transferased SD male rat ↓ to 11% ↓ to 43% No change —
Selenium-dependent glutathione peroxidased SD male rat ↓ to 66% ↓ to 76% No change —
Glutathione equivalentsd SD male rat No change ↓ to 66% No change —
Abbreviations: —, not tested; ↑, increased; ↓, decreased; DBP, dibutyl phthalate; SD, Sprague-Dawley. 
aResults are from Poole et al. (2001), Fan et al. (2003, 2004), and O’Brien et al. (2001) in which F-344 rats, Sprague-Dawley rats, or SV129 PPARα (+/+) or (–/–) “null” or “knockout” mice were
exposed for 13 (rats) or 3 (mice) weeks. Rats received control diet, 500 ppm WY, 8,000 ppm GEM, or 20,000 ppm dibutyl phthalate in the diet. Mice received control diet, 0.1% WY, or 0.6%
DEHP in diet. bResults from Fan et al. (2004) and Poole et al. (2001) included two sets of experiments for Sprague-Dawley rats. cNo quantitative number given but reported to be statistically
signiﬁcant. Testosterone hydroxylase activities are derived from hepatic microsomes. dExposure level of GEM is 16,000 ppm. Parameters investigated in the liver include NADPH–CYP oxi-
doreductase, an often rate-limiting component in CYP-dependent reactions; nonspecific carboxyesterases, a large group of enzymes that play important roles in the metabolism of
endogenous lipids and foreign compounds such as pesticides and drugs; phase I and II steroid metabolism enzymes; and glutathione and glutathione-related enzyme activities.potential MOA of liver cancer induction, but
concerns have been raised regarding the ade-
quacy of this model. These are related to both
existing study designs (e.g., a less-than-life-
time analysis of tumor induction) and to
whether the intrinsic characteristics of these
knockout mice mean that they exhibit
responses that differ from those of wild-type
mice independent of effects related to PPARα
agonism. The recent study by Laughter et al.
(2004), discussed above, illustrates the poten-
tial difficulties in interpreting studies using
knockout mice.
Huss and Kelly (2004) reported massive
cardiac lipid accumulation and hepatic steato-
sis in PPARα knockout mice after fasting or
pharmacologic inhibition of fatty acid oxida-
tion. Such mice have reduced cardiac expres-
sion of genes involved in the cellular uptake,
mitochondrial transport, and mitochondrial
(and peroxisomal) oxidation of fatty acids.
After exposure to stress, PPARα knockout
mice have decreased ATP concentration with
abnormal cristae of the mitochondria, abnor-
mal caveolae, and ﬁbrosis in the myocardium
in an age-dependent manner (Watanabe et al.
2000). After partial hepatectomy, PPARα
knockout mice have a 12- to 24-hr delay in
liver regeneration and hepatic gene expression
with a delayed onset and lower peak mag-
nitude of hepatocellular DNA synthesis
(Anderson et al. 2002). Furthermore, these
mice had a 24-hr lag in the hepatic expression
of the G1/S checkpoint regulator genes cyclin
D1 (Ccnd1) and c-myc and increased expres-
sion of the interleukin-1β cytokine gene
(genes involved in cell cycle control, cytokine
signaling, and fat metabolism). Epidermal
regeneration has also been reported to be
affected in PPARα knockout mice (Michalik
et al. 2001, 2002).
Costet et al. (1998) reported that with sta-
ble caloric intake, PPARα knockout mice were
a model of monogenic, spontaneous, late-onset
obesity, with a marked sexual dimorphism.
Increased serum triglycerides, cholesterol, and
phosholipids were elevated in aged PPARα
knockout mice, with higher serum triglycerides
in females. Females also developed a more pro-
nounced obesity than did males but no steato-
sis. Males showed a marked steatosis restricted
to the centrilobular region, a delayed occur-
rence of obesity, and larger elevation in hepatic
cholesterol and triglycerides than did females
or wild-type mice. By 302 days, normal hepa-
tocytes were restricted to periportal zones. All
animals showed an increase in all fat tissues
(including brown fat).
Shankar et al. (2003) also reported
PPARα knockout mice to have significant
steatosis without treatment. Lewitt et al.
(2001) reported PPARα knockout mice to
have a sexually dimorphic phenotype, with
PPARα influencing the IGF/IGF-binding
protein response to feeding, particularly in
males, and suggested that gender differences
in the IGF system contribute to the PPARα
knockout phenotype. It has been suggested
that elevated serum levels of IGF1 and leptin
are associated with increased risk of develop-
ing cancer (Hursting et al. 2003; Liu et al.
2001; Sandhu et al. 2002; Thompson et al.
1999). Not only are hepatocytes abnormal
and adversely affected from knockout of the
PPARα gene, but full expression of carcino-
genicity, especially by weaker agonists, may be
limited by decreased survival [i.e., untreated
knockout mice begin to die by age 3 months,
with a 50% mortality rate by 6 months and
100% mortality rate by 11 months of age
(Nohammer et al. 2003)].
Intrinsic factors that may affect PPAR-
mediated risks. Important considerations in
trying to determine the potential effects of
PPAR agonists and how they may contribute
to TCE toxicity and risk are the intrinsic fac-
tors that affect that risk. Modulation of
PPAR-mediated risks by intrinsic factors such
as genetic polymorphisms, disease states, and
life stages may give important clues about key
steps in their MOAs and the effects of ago-
nism or changes in receptor function. A num-
ber of recent studies are summarized below
that are representative of the issues currently
under investigation. Although a deﬁnitive pic-
ture has yet to emerge, the investigations of
polymorphic responses in particular could be
informative of potential human uncertainty
and variability in susceptibility to a number
of end points and targets besides the liver.
Graham et al. (2004) recently reported sig-
niﬁcantly increased incidence of hospitalized
rhabdomyolysis in patients treated with ﬁbrates
both alone and in combination with statins.
Brisson et al. (2002) suggest that frequent
genetic variations in genes encoding proteins
involved in triglyceride-rich lipoprotein
metabolism could modulate the response to
fenofibrate treatment, as defined in clinical
guidelines. Robitaille et al. (2004) reported
that the PPARα-L162V polymorphism alone
or in interaction with dietary fat intake was
associated with components of the metabolic
syndrome. Vohl et al. (2000) reported an asso-
ciation between the PPARα V162 allele and
the atherogenic/hyperapolipoprotein B dys-
lipidemia. Jamshidi et al. (2002) reported that
variation in the PPARα gene influenced
human left ventricular growth in response to
exercise and hypertension, indicating that
maladaptive cardiac substrate use can play a
causative role in the pathogenesis of left
ventricular hypertrophy. Eurlings et al. (2002)
reported that the PPARα gene was a modiﬁer
of the familial combined hyperlipidemia phe-
notype [a common genetic lipid disorder pre-
sent in 10% of patients with premature
coronary artery disease (CAD)]. Lacquemant
et al. (2000) screened the PPARα gene for
mutations to test the genetic contribution of
the PPARα in diabetes and its vascular compli-
cations and concluded that it is unlikely that
the PPARα gene had a major role in diabetes
and CAD in their populations.
Huss and Kelly (2004) suggested that
PPARα and PPARβ are primary regulators of
fatty acid metabolism in the heart and that
disturbances of PPARα either through inacti-
vation or chronic stimulation can have delete-
rious effects, particularly in the context of
diabetes, hyperlipidemic states, or the ischemic
heart. The insulin-resistant and diabetic heart
is characterized by increased fatty acid oxida-
tion rates that may be related to chronic stim-
ulation of the PPARα gene regulatory
pathway. Mice genetically modiﬁed to mimic
the metabolic derangements of the diabetic
heart (i.e., cardiac-specific overexpression of
PPARα) (Harris et al. 2004) had ventricular
diastolic/systolic dysfunction at baseline,
which was exacerbated by high-fat feeding or
insulinopenia, and developed cardiomyopa-
thy. Jove et al. (2004) reported that decrease
of mtDNA content has been related to the
pathogenesis of type 2 diabetes mellitus and
showed increased expression of PPARα and its
target genes to be involved in fatty acid metab-
olism in skeletal muscle of Zucker diabetic
fatty rats. Asayama et al. (1999) have reported
PPARα expression and activity to be increased
in diabetic rat liver.
Regarding life stages, there is also evidence
that peroxisome proliferators are much more
potent in producing tumors in older rats than
in younger ones, even though effects on PP
and cell proliferation were the same (Chao
et al. 2002; Youssef and Badr 2002; Youssef
et al. 2003). A promotion effect in older ani-
mals with already initiated foci could be the
MOA for increased sensitivity of older rats to
PPARα effects. Specific time- and tissue-
dependent patterns of PPARα, PPARδ, and
PPARγ expression have been shown during
fetal development and in adult animals
(Michalik et al. 2001, 2002). Data on humans
are limited. Other factors in the developing
rodent or human (i.e., differences in cell prolif-
eration, xenobiotic metabolism) could affect
sensitivity to PPARα hepatocarcinogenesis.
Ring et al. (1999) reported that in addition to
differences in metabolic enzymes, the fetal liver
has a unique physiologic milieu (e.g., fetal
hepatic circulation and zonation of drug-
metabolizing enzymes along the hepatic acinus
differs substantially from the adult). Placental
transfer of the cloﬁbrate with increased PP and
CYP4A mRNA has been demonstrated in
both maternal and fetal livers (3-fold mRNA
elevation in fetuses) (Simpson et al. 1996), as
has translactational induction of CYP4A
expression by clofibrate in neonatal rats
(Simpson et al. 1995).
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The studies reviewed here suggest that, given
its pleiotropic responses, PPARα agonism may
play a complex role in cell signaling and gene
expression changes that contribute to a variety
of different diseases and effects. Unfortunately,
common patterns of gene expression changes
among TCE, its metabolites, and other
PPARα agonists, particularly those related to
tumorigenic responses, have yet to be identi-
ﬁed, precluding their use in delineating com-
mon MOAs. Recent data also suggest that even
for liver tumor induction, extraperoxisomal
effects such as changes in mitochondria and
activation of Kupffer cells may play an impor-
tant role, so inferences based on PP or puriﬁed
hepatocyte cultures alone may be misleading.
Recent studies also suggest that knockout and
wild-type mice have baseline differences in liver
parameters before treatment and exhibit differ-
ences in response to agonists, including TCE
and its metabolites, independent of the peroxi-
somal effects, making interpretation of such
studies challenging. On the whole, recent stud-
ies suggest that inferences regarding the
MOA(s)—and hence the human relevance and
susceptibility—of TCE-induced effects require
a better understanding of the interplay of
extraperoxisomal events after PPARα agonism.
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